NASDAQ:OCGN
Ocugen Stock News
$1.59
-0.0800 (-4.79%)
At Close: May 10, 2024
Why Ocugen Is Climbing Today
12:25pm, Wednesday, 13'th Jul 2022
India will soon be giving away doses of Covaxin for free.
Why Ocugen Stock Is Sinking Today
11:20am, Tuesday, 12'th Jul 2022
What goes up can come down.
Why Ocugen Stock Ascended Today
04:48pm, Friday, 08'th Jul 2022
Its collaborator in India got a thumbs-up from regulators.
Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years
10:25am, Tuesday, 21'st Jun 2022
Ocugen Inc (NASDAQ: OCGN) announced the publication of positive pediatric Phase 2/3 study results in children aged 2–18 years for COVID-19 vaccine, Covaxin (BBV152), in The Lancet Infectious Dise
Why Ocugen Stock Flopped on Friday
06:39pm, Friday, 10'th Jun 2022
Shareholders could be hit with a high degree of stock dilution soon.
Ocugen, Inc. to Present at BIO International Convention 2022
06:17pm, Thursday, 09'th Jun 2022
MALVERN, Pa., June 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vacc
Will This Beaten-Down Stock Bounce Back? 3 Things to Know
06:30am, Saturday, 28'th May 2022
Ocugen shares soared when it first entered the coronavirus vaccine race.
Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA
12:48pm, Tuesday, 24'th May 2022
Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).
Ocugen Diversifies Its Pipeline With New Cell Therapy Platform
09:41am, Tuesday, 24'th May 2022
Ocugen Inc (NASDAQ: OCGN) says it is diversifying its pipeline by introducing a Phase 3 cell therapy platform technology called NeoCart (autologous chondrocyte-derived neocartilage). Recently, th
OCGN Stock Falls Despite Positive FDA Update
10:41am, Monday, 23'rd May 2022
Shares of the biotech company are falling despite news that the FDA has cleared it to resume clinical trials of its Covid-19 vaccine. The post OCGN Stock Falls Despite Positive FDA Update appeared fir
FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial
08:57am, Monday, 23'rd May 2022
The FDA has lifted the clinical hold on Ocugen Inc's (NASDAQ: OCGN) Phase 2/3 trial, OCU-002, for Covaxin (BBV152), a whole virus inactivated COVID-19 vaccine candidate. In April, the agency pause
Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference
07:34am, Monday, 23'rd May 2022
MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccin
Is Ocugen Finally on the Way to Vaccine Revenue?
06:30am, Wednesday, 18'th May 2022
It's entering a new market -- one that has authorized its vaccine.
Where Will Ocugen Be in 1 Year?
07:10am, Friday, 13'th May 2022
Can the company return to its 2021 highs?
Ocugen, Inc. (OCGN) CEO Shankar Musunuri on Q1 2022 Results - Earnings Call Transcript
08:56pm, Friday, 06'th May 2022
Ocugen, Inc. (NASDAQ:OCGN ) Q1 2022 Earnings Conference Call May 6, 2022 8:30 AM ET Company Participants Ken Inchausti - Head, Investor Relations & Communications Shankar Musunuri - Chairman, Chief Ex
